Get the Stockscreener App
4.685
15.16%
0.595
Annovis Bio Inc stock is traded at $4.685, with a volume of 1.55M.
It is up +15.16% in the last 24 hours and up +129.77% over the past month.
Annovis Bio Inc is a clinical-stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neurodegenerative diseases. The pipeline products of the company consists of: Buntanetap for chronic neurodegeneration - including AD and PD; ANVS405 for acute neurodegeneration; and ANVS301 for AD.
See More
Previous Close:
$4.09
Open:
$4.08
24h Volume:
1.55M
Relative Volume:
1.00
Market Cap:
$124.17M
Revenue:
-
Net Income/Loss:
$-30.26M
P/E Ratio:
-2.2966
EPS:
-2.04
Net Cash Flow:
$-24.69M
1W Performance:
+39.77%
1M Performance:
+129.77%
6M Performance:
+137.89%
1Y Performance:
-33.38%
1-Day Range:
$4.01
$4.74
1-Week Range:
$3.25
$4.74
52-Week Range:
$1.11
$7.39
Annovis Bio Inc Stock (ANVS) Company Profile
Name
Annovis Bio Inc
Sector
Industry
Phone
484-875-3192
Address
101 LINDENWOOD DRIVE, SUITE 225, MALVERN, PA
Compare ANVS with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ANVS
Annovis Bio Inc
|
4.685 | 108.40M | 0 | -30.26M | -24.69M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
428.94 | 107.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.23 | 80.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
431.13 | 57.37B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
908.04 | 55.83B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
207.22 | 44.13B | 447.02M | -1.18B | -906.14M | -6.1812 |
Annovis Bio Inc Stock (ANVS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-10-25 | Downgrade | D. Boral Capital | Buy → Hold |
| Oct-25-24 | Upgrade | Maxim Group | Hold → Buy |
| Dec-29-23 | Initiated | Canaccord Genuity | Buy |
| Jul-07-21 | Reiterated | Maxim Group | Buy |
Annovis Bio Inc Stock (ANVS) Latest News
Alzheimer's Disease Market to Evolve Rapidly Over the Next - openPR.com
Annovis Bio director Hoffman buys $159k in shares - Investing.com
Parkinson’s Breakthrough? New Data Shows Drug May Reverse Cognitive Decline - MyChesCo
Annovis Announces Two Presentations at the CTAD 2025 Conference - The Manila Times
Annovis Bio director Hoffman buys $69.9k in ANVS stock By Investing.com - Investing.com Nigeria
Annovis Bio director Hoffman buys $69.9k in ANVS stock - Investing.com
Will Annovis Bio Inc. stock attract long term capital inflows2025 Short Interest & Intraday High Probability Setup Alerts - newser.com
How Annovis Bio Inc. stock reacts to stronger dollarJuly 2025 Technicals & Long-Term Safe Investment Ideas - newser.com
Annovis Bio Inc Stock Analysis and ForecastDividend Stability Analysis & Small Budget Capital Growth - earlytimes.in
How Annovis Bio Inc. stock reacts to monetary easingTake Profit & Verified Momentum Watchlists - newser.com
Why Annovis Bio Inc. stock fits value portfoliosWeekly Earnings Recap & Fast Entry Momentum Alerts - newser.com
Can Annovis Bio Inc. stock deliver sustainable ROEWeekly Stock Report & Daily Volume Surge Trade Alerts - newser.com
Will Annovis Bio Inc. stock benefit from automationJuly 2025 Closing Moves & AI Forecasted Stock Moves - newser.com
Will Annovis Bio Inc. stock outperform Dow JonesShare Buyback & Detailed Earnings Play Alerts - newser.com
Why Annovis Bio Inc. stock is a must watch tickerShare Buyback & Scalable Portfolio Growth Ideas - newser.com
How Annovis Bio Inc. stock compares with market leadersJuly 2025 Patterns & Community Supported Trade Ideas - newser.com
Is Annovis Bio Inc. stock attractive for passive investors2025 Trade Ideas & AI Powered Market Entry Strategies - newser.com
How Annovis Bio Inc. stock compares with top peers2025 Dividend Review & Free High Accuracy Swing Entry Alerts - newser.com
Annovis Stock Rises After Company Confirms Meeting With Regulators To Discuss Drug In Treating Parkinson's Disease Dementia - MSN
Can momentum traders help lift Annovis Bio Inc.July 2025 PostEarnings & High Yield Stock Recommendations - newser.com
FDA to hear plan for buntanetap as Parkinson’s dementia treatment - Parkinson's News Today
What does recent volatility data suggest for Annovis Bio Inc.July 2025 Snapshot & Stepwise Entry/Exit Trade Alerts - newser.com
Annovis Bio Inc. stock volume spike explainedJuly 2025 Volume & Daily Stock Trend Watchlist - newser.com
Can Annovis Bio Inc. stock deliver consistent EPS growth2025 Price Action Summary & Intraday High Probability Setup Alerts - newser.com
Applying Wyckoff theory to Annovis Bio Inc. stockJuly 2025 Breakouts & Verified Chart Pattern Signals - newser.com
Annovis Rallies Around Phase 3 Alzheimer’s Push as New Data Signals Disease-Modifying Promise - MyChesCo
Why retail traders accumulate Annovis Bio Inc. stockQuarterly Trade Summary & Daily Technical Stock Forecast Reports - newser.com
How geopolitical risks impact Annovis Bio Inc. stockEarnings Overview Report & Accurate Technical Buy Alerts - newser.com
Annovis Bio Inc Stock (ANVS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.50%
1.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):